v3 Template
C

CRISPR QC

Biotechnology ~400 employees
Founded
--
Employees (Est.)
~400
20 leaders known
Total Funding
$20.0M
Funding Rounds
2
Last Funding
2024-01-05

About CRISPR QC

CRISPR QC is a company focused on transforming gene editing workflows by providing real-time kinetic insights through their CRISPR Analytics Platform™. Their mission is to maximize efficiency from discovery to commercialization, empowering discovery, development, and manufacturing with quantitative data to optimize CRISPR processes and accelerate breakthroughs.

Products & Services

CRISPR Analytics Platform™:A platform providing real-time insights into RNP formation, DNA target binding kinetics, cleavage activity, and more to optimize CRISPR workflows.
Insight Solutions - RNP Formation:Direct measurement of nucleic acid-protein interactions to pre-screen gRNA efficiency, RNP assembly, and stability.
Insight Solutions - DNA Target Binding:Real-time measurement of binding activity between target DNA amplicons and RNP complexes to optimize gRNA designs and binding efficiency.
Insight Solutions - CLEAVE:Highly sensitive detection of CRISPR-Cas cleavage activity in real-time to quantify cleavage efficiency and increase reproducibility.
Bioprocessing Solutions:Solutions to optimize CRISPR-based bioprocessing workflows.
CRISPR-Chip™:A cutting-edge graphene-based biosensor chip for quantitative in vitro analysis of CRISPR-Cas biochemistry.

Specialties

CRISPR gene editing Real-time kinetic insights RNP formation analysis DNA target binding kinetics Cleavage activity measurement Graphene-based biosensor technology

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Series A
T: -
FT: Series A 		A: 10000000
MR: -
FA: $10 million
FAN: 10000000 		D: 2024-01-05
FD: 2024-01-05 		1 investors
2 RT: Series A
T: -
FT: Series A 		A: 10000000
MR: -
FA: $10,000,000
FAN: 10000000 		D: 2024-01-04
FD: 2024-01-04 		1 investors
Series A Latest
2024-01-05
$10.0M
1 investor (Pro only)
Series A 2024-01-04
$10.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

R

Ross Bundy

President and CEO, Co-founder

LinkedIn (Pro only)
T

Tim Cloutier

Chief Commercial Officer

LinkedIn (Pro only)
S

Susan Pede

VP Operations

LinkedIn (Pro only)
C

Chad Trytten

VP Technology

K

Ken Dickerson

Head of Global Sales

J

Jason Lehmann

Sr Product Marketing Manager

View 17 more team members with Pro

Unlock Full Team Directory

Recent News

CRISPR QC Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology
Company Size
~400 employees (est.)

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro